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Clinics and pathology 
Disease 
Atypical chronic myeloid leukemia (a-CML). 
Epidemiology 
Only one case to date with ascertainment of the genes 
involved (another case was a 18 year old female pati nt 
with a M2 acute non lymphocytic leukemia (ANLL) 
and a t(7;11)(p15;p15) ; the t(5;14) appeared at rel ps , 
5 months before death, 27 months after diagnosis). 
Clinics 
The sole case of t(5;14)(q33;q32) with certain 
PDGFRB/KIAA1509 involvement was a 42 year old 
male patient, BCR-ABL negative, treatad with 
imatinib, and maintained in complete remission 18 
mths after diagnosis. 




PDGFRB is the receptor for PDGFB (platelet-derived 
growth factor-b); Ig like, transmembrane and tyrosine 













5' KIAA1509 - 3' PDGFRB; breakpoint in PDGFRB 
intron 10, identical to most PDGFRB breakpoints. 
Fusion protein 
Description 
934 amino acids composed of the 355 amino acids 
from KIAA1506 in N-term and 579 amino acids from 
PDGFRB C-term. 
Oncogenesis 
The coiled coil domain may mediate PDGFRB 
homodimerization and constitutive activation. 
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